OxyPharma

OxyPharma AB, Box 47041, S-100 74 Stockholm, Sweden. Visiting address: Nybohovsbacken 23-25.
info@oxypharma.com, tel +46 (0)8 726 17 02, fax +46 (0)8 18 28 03.

OxyPharma is a Swedish privately held drug discovery
company developing new drugs primarily for the treatment
of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). In
1998, based on preclinical results from the Company’s lead
compound B-220, studies were initiated to investigate its
effect in inflammatory and autoimmune disease models
for RA and MS.

Read more ››

OxyPharma's compounds are small molecules targeted for oral administration, differentiating the Company's potential therapies from almost all existing RA and MS therapies and most RA and MS drugs in late stage clinical development.

Read more ››

2008-06-20
OxyPharma Adds Clinics for its Rabeximod Study
OxyPharma has received regulatory clearance to start enrollment of patients in clinics in Poland and Georgia, which brings the number of participating countries to nine.